Cognition Disorders Completed Phase 2 / 3 Trials for Memantine (DB01043)

IndicationStatusPhase
DBCOND0027877 (Cognition Disorders)Completed2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00300716Trial of Memantine for Cognitive Impairment in Multiple SclerosisTreatment